Efficacy Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy Patients
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to assess the efficacy, safety, tolerability, and pharmacokinetics
(PK) of AVI-4658 (eteplirsen) in both 50.0 mg/kg and 30.0 mg/kg doses administered over 24
weeks in subjects diagnosed with Duchenne muscular dystrophy (DMD).